Clinical Trials on Resectable Intrahepatic Cholangiocarcinoma in Brazil

Total 29 results

Mirum Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, Argentina, France, Singapore, United Kingdom, Belgium, Turkey, Austria, Brazil, Canada, Colombia, Germany, Italy, Lebanon, Mexico, Poland
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
University of Sao Paulo General Hospital

Completed

Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine

Primary Biliary Cirrhosis | Ursodeoxycholic Acid

Brazil
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Taiho Oncology, Inc.

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)

Advanced Cholangiocarcinoma | FGFR2 Fusions | Gene Rearrangement

United States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Weill Medical College of Cornell University

Unknown

T-EUS for Gastrointestinal Disorders: A Multicenter Registry (EUSERCPReg)

Pancreatic Cancer | Cholangiocarcinoma | Bile Duct Cancer | Chronic Pancreatitis | Biliary Stricture | Biliary Obstruction | Ampullary Cancer | Stent Obstruction | Proximal Duct Stricture | Distal Duct Stricture | Biliary Sphincter Stenosis | Impacted Stones | Peri-ampullary Diverticula | Altered Anatomy

United States, Brazil
Bayer

Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (REFINE-IO)

Unresectable Hepatocellular Carcinoma

Greece, Spain, Brazil, China, Colombia, Italy, Saudi Arabia, Taiwan, Thailand, United States, Korea, Republic of, Argentina, France, Mexico, Turkey
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
Ipsen

Active, not recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Primary Biliary Cirrhosis

United States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
GlaxoSmithKline

Recruiting

Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

Cholestasis

United States, France, Japan, United Kingdom, Bulgaria, Germany, Greece, Italy, China, Argentina, Belgium, Brazil, Canada, Czechia, Israel, Mexico, Poland, Russian Federation, Spain, Switzerland
GlaxoSmithKline

Active, not recruiting

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Pruritus

United States, France, Spain, Israel, Belgium, Canada, Czechia, Italy, United Kingdom, China, Germany, Mexico, Japan, Brazil, Poland, Russian Federation, Greece, Argentina, Switzerland, Bulgaria
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

Metastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer

United States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, China, Argentina, Australia, Brazil, Chile, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Unresectable or Metastatic Melanoma

United States, Germany, Italy, United Kingdom, Canada, Denmark, Netherlands, Spain, Belgium, France, Switzerland, Israel, Austria, Brazil
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)

Stage III (Unresectable) or Stage IV Advanced Melanoma

United States, Canada, Argentina, Colombia, Peru, Brazil
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, Belgium, Korea, Republic of, Brazil, China, Croatia, Spain, Taiwan, Turkey, Italy, India, United Kingdom, Thailand, Costa Rica, Japan, France, Germany, Austria, Israel, Malaysia, Philippines, Estonia, Russian Federation, Greece, Bulgari... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
Pfizer

Completed

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Metastatic or Unresectable Cutaneous Melanoma

United States, Spain, Canada, Italy, United Kingdom, Germany, Korea, Republic of, France, Australia, Czechia, Russian Federation, Turkey, Israel, Netherlands, Greece, Hungary, Japan, Portugal, Argentina, Austria, Belgium, Brazil, Po... and more
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, Poland, United States, Canada, Japan, United Kingdom, Spain, China, France, Taiwan, Norway, Brazil, Germany, Switzerland, South Africa, Turkey, Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

United States, France, Canada, Spain, Italy, Belgium, Austria, Denmark, Germany, Australia, Israel, Russian Federation, Czechia, Norway, Poland, Romania, Japan, Argentina, Ireland, Greece, United Kingdom, Brazil, Sweden, Finland
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
HUYABIO International, LLC.
Bristol-Myers Squibb

Active, not recruiting

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma | Progressive Brain Metastasis

New Zealand, Spain, United States, Belgium, France, Japan, Germany, Korea, Republic of, Singapore, Australia, Brazil, South Africa, Italy, Czechia, Austria, Puerto Rico, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru

Clinical Trials on Resectable Intrahepatic Cholangiocarcinoma in Brazil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations